后程加速超分割放射治疗食管癌疗效荟萃分析

摘要

目的评价后程加速超分割放射治疗食管癌疗效。方法对6个后程加速超分割放射治疗食管癌临床试验进行Meta分析。结果采用固定效应模型计算，后超组1、3年生存率分别是常规组的 2.39 (1.58～3.62)、3.05(1.96～4.74)倍；采用随机效应模型计算，后超组1、3年生存率分别是常规组的2.43(1.54～3.82)、2.99(2.08～4.30) 倍。结论后程加速超分割放射治疗食管癌优于常规分割放射治疗，值得在临床上推广应用。%Objective　To evaluate the effect of late course accelerated hyperfractionation radiotherapy(LCAHR) for esophageal carcinoma. 　Methods　Six clinical trials on LCAHR for esophageal carcinoma were reviewed by means of Meta-analysis . 　Results　The 1- and 3-year survival rates in the LCAHR group derived from the fixed effect model were 2.39 (1.58～3.62) and 3.05(1.96～4.74) times higher than the conventional fractionation group. With the random effect model,the 1- and 3-year survival rates in the LCAHR group were 2.43(1.54～3.82) and 2.99(2.08～4.30) times higher than the conventional fractionation group.　Conclusion　For esophageal carcinoma,the better outcome of LCAHR makes it advisable in extensive clinical practice.